Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Ambry Genetics | RCV002330413 | SCV002633582 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2021-01-26 | criteria provided, single submitter | clinical testing | The c.463-1G>T intronic variant results from a G to T substitution one nucleotide upstream from coding exon 6 of the MUTYH gene. Alterations that disrupt the canonical splice site are expected to result in aberrant splicing. In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and may result in the creation or strengthening of a novel splice acceptor site. The resulting transcript is predicted to be in-frame and is not expected to trigger nonsense-mediated mRNA decay; however, direct evidence is unavailable. The exact functional effect of the missing amino acids is unknown; however, the impacted region is anticipated to result in a decrease in structural stability of the protein (Luncsford PJ et al. J Mol Biol, 2010 Oct;403:351-70; Ambry internal data). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This nucleotide position is highly conserved in available vertebrate species. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |